Publisher Correction: Therapies for rare diseases: therapeutic modalities, progress and challenges ahead

Affiliations

¹ BioPontis Alliance for Rare Diseases Foundation fup/son, Brussels, Belgium. erik@tambuyzer.be.
² BioPontis Alliance Rare Disease Foundation, Inc, Raleigh, NC, USA. erik@tambuyzer.be.
³ Byteflies, Antwerp, Belgium.
⁴ Department of Electrical, Computer, and Systems Engineering (ECSE), Case Western Reserve University, Cleveland, OH, USA.
⁵ National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.
⁶ Orphan Medicines Office, European Medicines Agency, Amsterdam, Netherlands.
⁷ Office of Orphan Products Development, Food and Drug Administration, Silver Spring, MD, USA.
⁸ Hyman, Phelps & McNamara, Washington, DC, USA.
⁹ MDUK Oxford Neuromuscular Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.
¹⁰ Hitachi Chemical Regenerative Medicine Business Sector, Allendale, NJ, USA.
¹¹ Translational Informatics Division, Department of Internal Medicine, University of New Mexico Albuquerque, Albuquerque, NM, USA.
¹² UNM Comprehensive Cancer Center, University of New Mexico Health Science Center, Albuquerque, NM, USA.
¹³ School of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland. marco.prunotto@unige.ch.

Published Erratum

Erik Tambuyzer et al. Nat Rev Drug Discov. 2020 Apr.

. 2020 Apr;19(4):291.

doi: 10.1038/s41573-019-0059-7.

¹ BioPontis Alliance for Rare Diseases Foundation fup/son, Brussels, Belgium. erik@tambuyzer.be.
² BioPontis Alliance Rare Disease Foundation, Inc, Raleigh, NC, USA. erik@tambuyzer.be.
³ Byteflies, Antwerp, Belgium.
⁴ Department of Electrical, Computer, and Systems Engineering (ECSE), Case Western Reserve University, Cleveland, OH, USA.
⁵ National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.
⁶ Orphan Medicines Office, European Medicines Agency, Amsterdam, Netherlands.
⁷ Office of Orphan Products Development, Food and Drug Administration, Silver Spring, MD, USA.
⁸ Hyman, Phelps & McNamara, Washington, DC, USA.
⁹ MDUK Oxford Neuromuscular Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.
¹⁰ Hitachi Chemical Regenerative Medicine Business Sector, Allendale, NJ, USA.
¹¹ Translational Informatics Division, Department of Internal Medicine, University of New Mexico Albuquerque, Albuquerque, NM, USA.
¹² UNM Comprehensive Cancer Center, University of New Mexico Health Science Center, Albuquerque, NM, USA.
¹³ School of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland. marco.prunotto@unige.ch.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Therapies for rare diseases: therapeutic modalities, progress and challenges ahead.
Tambuyzer E, Vandendriessche B, Austin CP, Brooks PJ, Larsson K, Miller Needleman KI, Valentine J, Davies K, Groft SC, Preti R, Oprea TI, Prunotto M. Tambuyzer E, et al. Nat Rev Drug Discov. 2020 Feb;19(2):93-111. doi: 10.1038/s41573-019-0049-9. Epub 2019 Dec 13. Nat Rev Drug Discov. 2020. PMID: 31836861 Review.